Methods. We synthesized the literature on clinical status of adults newly presenting to care for HIV infection in developed countries to generate an estimate of the time trend for CD4 cell count at the initiation of HIV care. We systematically searched PubMed for studies published between January 2000 and November 2011 to identify those that reported CD4 cell count for patients newly presenting to HIV care according to standardized inclusion criteria. We abstracted the mean or median CD4 cell count or reconstructed the mean CD4 cell count from the presented data describing the number or proportion of patients in CD4 cell count categories. We estimated the change in CD4 cell count over time by modeling it as a weighted linear function of calendar year.
The timing of diagnosis and presentation to medical care for persons infected with human immunodeficiency virus (HIV) has important consequences at the individual and population levels. Whether CD4 cell count or clinical indicators are used to determine the timing of presentation, the implications of "late presentation" have been consistent. At the individual level, persons who present to care later are at a higher risk for morbidity and mortality [1] and may not benefit from antiretroviral therapy (ART) to the same extent as persons who present earlier [2] . At a population level, timely entry to care has the potential to reduce HIV incidence [3] [4] [5] [6] . Late presenters also incur higher monetary costs for care, in both the short and long terms [7, 8] .
The goal of this systematic review is to provide a synthesis of trends in the clinical status of adults newly presenting to care for HIV infection in developed countries. We use CD4 cell count as an indicator of clinical status. Although the timing of presentation to clinical care may be described using a variety of endpoints, including clinical status at diagnosis and elapsed time between HIV diagnosis and presentation to medical care [9] , this review is focused on clinical status at care entry. Clinical status at entry to care is the indicator most reflective of the CD4 cell count at which individuals will begin ART, and thus is highly clinically relevant.
Over the history of the HIV epidemic, the importance of early diagnosis and prompt engagement in medical care has been a recurring theme. Within individual cohorts, there have been minimal improvements in the mean CD4 cell count over time [10] [11] [12] [13] [14] [15] , with some cohort studies observing a decline in immune status at the time of presentation to care [16] [17] [18] [19] [20] [21] [22] . To our knowledge, however, no systematic review has assessed temporal trends in the clinical status of persons presenting to HIV care across cohorts in developed countries.
METHODS
We conducted a search of the PubMed database in November 2011 for peer-reviewed, English-language manuscripts published from January 2000 through November 2011, including those published electronically ahead of print. Search criteria included at least 1 variation on the following words: presentation, entrance, delay, initiation, care, or diagnosis (in the title) and HIV or AIDS (in the title or as a medical subject heading term). Detailed search specifications are available upon request. We examined the references of papers identified in our search ("secondary references") and reviewed those that were potentially relevant but not included in our initial search results. We excluded studies conducted in nations that were not on the United Nations list of countries with "very high human development" (http://hdr.undp.org/en/statistics), studies done exclusively in pediatric populations, prenatal populations, persons already enrolled in HIV care, drug trials, case studies, seroconverter cohort studies, and studies of acute HIV infection. Studies were included in the review if they presented data on CD4 cell count for patients newly presenting to care for HIV infection. We did not require that the goal of the paper be the evaluation of trends in CD4 cell count over time. When multiple manuscripts presented results from the same cohort, only the paper with the most complete information on CD4 cell count trends was included.
A broad definition of "newly presenting to care" was utilized to allow for an inclusive description of the criteria from the abstracted studies. To be included in this review, there had to be evidence that persons were diagnosed and enrolled in medical care. For example, studies were not included if the cohort was defined as those seeking HIV testing services. Some authors treated initial entry to care and diagnosis as synonymous. For example, for persons seeking medical care at a particular clinic, patients might be designated as "new to care" if they were diagnosed with HIV by that clinic, or if they were diagnosed within a short window prior to enrollment in medical care. Alternately, patients were labeled "new to care" if they had no history of receiving care anywhere else, no history of opportunistic infections, or no history of ART. Because studies based on only persons with recent HIV diagnosis date would exclude persons who delayed seeking care for an extended period of time after diagnosis, we dichotomized studies according to the definition of "new to care" used. Studies with recent HIV diagnosis date as part of their inclusion criteria were distinguished from studies that based inclusion on medical history as indicated by attendance at facility for HIV medical care. We also dichotomized studies according to whether they were based on surveillance data or clinic-based data. For studies based on surveillance data, the report of a CD4 cell count to public health officials was used as a proxy for initiation of medical care and as the outcome. Surveillance data capture population-level trends but may capture CD4 cell counts not associated with HIV medical care, whereas clinic-based data only capture a subsample of newly diagnosed persons entering HIV care, which may be more or less representative of the entire population of new infections. Finally, we dichotomized studies according to whether they were conducted in the United States or elsewhere, assuming that differences in healthcare policy or practice may result in differences in trends in clinical status at presentation to HIV care.
We abstracted mean or median CD4 cell count in cells per microliter, or the number or proportion of patients with CD4 cell counts in particular ranges, stratified by the year of presentation to HIV care. For studies that presented only the number or proportion of patients in CD4 cell count categories, we approximated the mean CD4 cell count by taking a patientweighted average of the midrange of the categories. For unbounded upper categories, we assumed an upper bound of 850 cells/μL. We assigned the value of one-third of the implied range of the upper categories (rather than the midpoint) because of the likely skew in CD4 cell counts. When authors reported only the number of patients below a threshold CD4 cell count (eg, <200 cells/µL), we assumed that all patients not in another category of CD4 had a measured CD4 cell count in the upper CD4 cell count category. For example, if a study of 1000 persons reported that 36% had a CD4 count <200 cells/μL, and Because the number of time points for which CD4 cell count was estimated varied across studies, with some including only one time point, we chose to meta-estimate one temporal trend from all the studies, accounting for correlations among multiple time intervals within studies, rather than estimating separate time trends within each and meta-analyzing those. We used meta-regression to model CD4 cell count as a weighted linear function of calendar year, including each abstracted estimate for a given calendar time interval as a unique data point and assigning calendar year based on the midrange of the calendar interval for which the estimate was calculated. We used the mean CD4 cell count if reported, our reconstructed mean CD4 cell count if no mean was reported, or the median CD4 cell count if neither of these were available. Ideally, we would have weighted by the inverse variance of each mean, but the variance of the mean was rarely reported. Instead, we assumed that each of the inverse variance weights would be approximately proportional to the number of persons, and we weighted each estimate by the number of patients with a measured CD4 cell count entering care in the interval, or the total number of patients entering HIV care in the interval when the number with a measured CD4 cell count was not reported. To accurately place estimates in time, we restricted our model to estimates in which the calendar interval over which CD4 cell count was measured was ≤5 years. We restricted our analysis to estimates from 1992 to 2011. If a single study presented some estimates that fit these criteria and others that did not, estimates that fit the criteria were included. We used indicators in our model for the type of data used (surveillance or clinical), the inclusion criteria used to define new to care (HIV diagnosis date or medical history), and the CD4 cell count measure (mean or median), as well as interactions between each of these indicators and calendar time to detect differences in the slope of the trend associated with study characteristics. To account for variance between and within studies, we used nonparametric bias-corrected and accelerated bootstrapped 95% confidence intervals (CIs) [23] ; we generated 2000 random samples with replacement of the abstracted estimates, clustered by the study from which they were drawn, fit the linear meta-regression for each sample, and used the parameter estimates from each of the models to estimate the variance of the original estimates.
Acknowledging the efforts of the UK Collaborative HIV Cohort Steering Committee [1] and the European Working Group on late presentation [24] to standardize how clinical status at presentation to care is measured, we also abstracted the proportion of patients classified as "late presentation" (presentation with a CD4 count of <350 cells/μL or an AIDS-defining condition) and the proportion classified as "presentation with advanced HIV disease" (presentation with a CD4 count <200 cells/ μL or an AIDS-defining condition). As with the CD4 count estimates, we used meta-regression to model each proportion as a weighted linear function of calendar year, including each abstracted estimate as a unique data point and assigning calendar year based on the midpoint of the calendar interval for which the estimate was calculated. For the meta-regression of proportions, we used inverse-variance weights: n/( p*(1-p)), where n is the number of persons used to generate the estimate, and p is the proportion of persons classified as "late presentation" or "presentation with advanced HIV disease."
All analyses were conducted with SAS software, release 9.1 (SAS Institute Inc, Cary, North Carolina).
RESULTS
The original search returned 3201 publications. On the basis of title alone, the number of publications was trimmed to 201; following abstract and full text review, the number of abstracted studies was 51, including 6 secondary references. Seven studies were excluded because they did not define how they ensured patients were new to care [21, [25] [26] [27] [28] [29] [30] , leaving 44 studies in this meta-regression [10-20, 22, 31-61] (Table 1) .
The United States (n = 18) and the United Kingdom (n = 11) yielded the largest number of studies. The majority of the included studies were based on medical records data (n = 31). Roughly one-third (n = 13) were based on surveillance data. More than half (n = 30) used a proximal HIV diagnosis to classify persons as new to care. Fourteen studies defined "new to care" on the basis of medical history. Specific definitions of new to care and inclusion/exclusion criteria varied such that they were not collapsible beyond the crude dichotomous categorizations described in the Methods ( Table 1 ). The number of interval estimates contributed per study ranged from 1 to 15 (mean = 4.5). The average interval length was 2.4 years. There was an average of 12.3 estimates per year (range, 1-21) over the 20-year study period.
Most publications presented a categorical summary of CD4 cell count (n = 33), although the specific categories varied. The most common were <200 CD4 cells/µL and <350 CD4 cells/µL. Eleven studies reported the overall mean CD4 cell counts, and 32 studies reported median CD4 cell counts. Seven studies contained both categorical CD4 cell count data as well as the mean CD4 cell count. In these studies, a reconstructed mean CD4 cell count derived from the categorical data was on average 3.5 cells/μL higher than the reported mean (SD, 32.4). Six studies yielded 18 estimates of the proportion presenting with advanced HIV disease (CD4 count <200 cells/µL or AIDS), and 4 studies yielded 29 period estimates of the proportion presenting late to HIV care (CD4 count <350 cells/μL or AIDS).
The unadjusted estimated change in CD4 cell count was +1. Table 2 ). Adding a quadratic term for time to the model did not substantially change the shape of the trend (coefficient for the quadratic term: 0.41 [95% CI, −0.6 to 1.4]) nor substantially improve model fit (P = .12). There was no evidence of modification of the CD4 cell count time trend by each of the 3 different study criteria (type of data used in the study, inclusion criteria used to define new to care, and location of the study) in 3 separate models, adjusting for all 3 study criteria in each model (Figure 2 , Table 3 ). In sensitivity analyses, results were robust to analysis choices. Exclusion of studies that reported only median CD4 cell counts yielded a similar estimate of the trend (unadjusted estimate: + 1.9 cells/μL [95% CI, −3.4 to 7.8 cells/μL]). When we varied the upper limit for CD4 cell count used to reconstruct a mean CD4 cell count from a categorical summary between 600 and 1200, results were similar. Because data were relatively sparse at the The estimated change in the proportion of persons presenting with advanced HIV disease (CD4 cell count <200 cells/μL or AIDS) and in the proportion of persons presenting late (CD4 cell count <350 cells/μL or AIDS) were both <0.1% per year. The 2 meta-regression models were based on too few studies to derive a valid estimate of the variance.
DISCUSSION
The time period covered by this review spanned several major advances in HIV diagnosis, prevention, and clinical care, including the implementation of rapid HIV tests, the proliferation of HIV testing initiatives, the increase in HIV testing in Figure 1 . Mean CD4 cell count (cells/µL) by calendar year of presentation to human immunodeficiency virus medical care from 44 studies presenting estimates in which the calendar time interval was ≤5 years and the midrange of the estimate was between 1992 and 2011. Bubbles represent estimated mean CD4 cell counts from individual studies and are plotted on the midpoint of the interval over which they were measured. The size of the bubble is proportional to the number of patients included in calculating the estimate. The line is the predicted mean CD4 cell count per year from the described meta-regression. The formula for the regression line is printed in the frame. nontraditional testing sites, the introduction and refinement of ART, and several major expansions of programs that provide low-or no-cost access to HIV testing, prevention, and medical care. Despite these advances, our systematic review did not
show that persons with HIV in the developed world are presenting to care earlier in the course of their infection. Although we attempted to distinguish between diagnosis and entry to care, most studies did not use inclusion criteria that clearly defined the time point at which persons were evaluated. Using recent diagnosis as a proxy for care entry excludes patients with a long interval between diagnosis and first clinical visit (delayed presentation). Although our conclusions did not change based on the definition of "new to care" that was used, future studies of late diagnosis or late presentation to care should clearly define a measurement strategy to facilitate detection of important differences between these 2 points on the HIV care continuum.
These findings are highly germane to recent enthusiasm for HIV treatment as prevention [62] , and indicate that the promise of such approaches is unlikely to be realized unless improvements in timeliness of HIV diagnosis and presentation for care are achieved, dramatically altering the trajectory of temporal trends observed over the last 2 decades. These findings are also relevant to contemporary clinical considerations. In recent years, the optimal timing of ART initiation has been extensively studied and discussed. Several guidelines have recommended ART initiation at higher CD4 counts (Department of Health and Human Services and International Antiviral Society-USA), whereas others maintain a threshold of 350 cells/µL (British HIV Association) [63] . Our study findings indicate that the consideration of when to start may be immaterial for the majority of patients who continue to enter care below any of the recommended treatment thresholds. Unless dramatic improvements in observed trends in clinical status at HIV care entry are achieved, results of these studies and discussions may have limited application.
Our analyses were limited by the information provided by each of the included studies. Studies reported a variety of measures to describe the distribution of CD4 cell count in their study population. To facilitate comparison, we reconstructed mean CD4 cell counts or used median CD4 cell counts when mean CD4 cell count was not reported. The decision to conduct a single meta-regression model based on 3 different outcomes allowed us to include many more studies than if we had been more restrictive, but may have introduced some imprecision in our estimates. Despite these limitations, our estimate was robust to decisions about how to reconstruct the mean CD4 cell count and whether or not to include median estimates in the analysis. Because only a handful of studies reported any variance estimates for the reported mean CD4 cell count, our study was unable to detect any differences in the overall distribution of CD4 cell count beyond basic shifts in its central location. Characteristics such as age, sex, and likely route of transmission have been associated with CD4 cell count at presentation to HIV care [64] , and differences in the Figure 2 . Mean CD4 cell count (cells/µL) by calendar year of presentation to human immunodeficiency virus medical care from 44 studies presenting estimates in which the calendar time interval was ≤5 years and the midrange of the estimate was between 1992 and 2011. A, According to whether new to care was defined based on medical history (black) or diagnosis date (gray); B, according to whether the data source was surveillance data (black) or clinic data (gray); and C, according to whether the study was conducted in the US (black) or elsewhere (gray). Bubbles represent estimated mean CD4 cell counts from individual studies and are plotted on the midpoint of the interval over which they were measured. The size of the bubble is proportional to the number of patients included in calculating the estimate. The shading of the bubbles corresponds to the specified study characteristic. The lines are the predicted mean CD4 cell count per year from the described meta-regression, stratified by the study characteristic. The formulas for the regression lines are printed in the frame.
populations studied over time may have influenced our reported meta-trend. Although we were unable to adjust for population demographics, most studies were based on a fairly heterogeneous population with respect to basic demographics, and a subanalysis of the data where demographics were available yielded similar results. Finally, some speculate that HIV has grown more slightly virulent (eg, −4.9 cells/μL per year) [65] . Such a slight increase in virulence might offset a weak trend in earlier presentation to care as measured by CD4 cell count. However, such a weak trend would not be clinically meaningful. Given that most of the data included in this study were abstracted from publications in which the primary purpose was not to report trends in CD4 cell count, we do not believe these results to be subject to publication bias.
We observed no significant trend over the past 2 decades in patients' CD4 cell count at first presentation to HIV care. Population shifts in CD4 cell count at initial presentation are likely to be gradual. Future studies should define the timing of their endpoint precisely and present the observed distribution of CD4 cell count to enable enhanced detection of temporal trends in clinical status at care entry. New and innovative strategies to identify persons earlier in the course of their HIV infection and link them promptly with medical care are clearly necessary and desperately needed to fully realize the individual and public health benefits afforded by contemporary HIV treatment. 
Notes

